Cerecor Inc (NASDAQ:CERC) Major Shareholder Armistice Capital Master Fund Buys 50,000 Shares

Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were bought at an average price of $5.47 per share, for a total transaction of $273,500.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Friday, March 8th, Armistice Capital Master Fund acquired 374,486 shares of Cerecor stock. The shares were bought at an average price of $5.50 per share, for a total transaction of $2,059,673.00.
  • On Monday, December 31st, Armistice Capital Master Fund acquired 38,799 shares of Cerecor stock. The shares were bought at an average price of $3.14 per share, for a total transaction of $121,828.86.

Shares of CERC stock traded up $0.13 during trading on Friday, reaching $5.33. 36,045 shares of the company’s stock were exchanged, compared to its average volume of 100,859. The company has a current ratio of 0.84, a quick ratio of 0.79 and a debt-to-equity ratio of 0.69. Cerecor Inc has a twelve month low of $2.71 and a twelve month high of $7.65. The firm has a market capitalization of $227.35 million, a PE ratio of 12.69 and a beta of 2.26.

CERC has been the topic of a number of analyst reports. HC Wainwright set a $11.00 price objective on Cerecor and gave the stock a “buy” rating in a research note on Wednesday. LADENBURG THALM/SH SH reissued a “buy” rating and set a $9.00 target price on shares of Cerecor in a report on Thursday, January 17th. ValuEngine lowered Cerecor from a “strong-buy” rating to a “buy” rating in a report on Friday, February 8th. TheStreet raised Cerecor from a “d” rating to a “c-” rating in a report on Wednesday, January 30th. Finally, BidaskClub raised Cerecor from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $10.00.

A number of hedge funds and other institutional investors have recently modified their holdings of CERC. Cambridge Investment Research Advisors Inc. acquired a new position in Cerecor in the 3rd quarter valued at $169,000. Vanguard Group Inc grew its holdings in shares of Cerecor by 10.1% during the 3rd quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock worth $411,000 after purchasing an additional 8,094 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Cerecor by 18.5% during the 4th quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock worth $109,000 after purchasing an additional 5,293 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Cerecor by 47.9% during the 4th quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock worth $65,000 after purchasing an additional 6,500 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Cerecor by 50.7% during the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock worth $306,000 after purchasing an additional 31,951 shares in the last quarter. 50.26% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Cerecor Inc (NASDAQ:CERC) Major Shareholder Armistice Capital Master Fund Buys 50,000 Shares” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/insider-buying-cerecor-inc-cerc-major-shareholder-acquires-273500-00-in-stock.html.

About Cerecor

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Further Reading: Trading based on a resistance level

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.